Columbia University Medical Center Minority-Based Community Clinical Oncology Pro

描述(申请人提供)：哥伦比亚大学医学中心赫伯特·欧文综合癌症中心位于纽约曼哈顿北部。在我们社区，71%的西班牙裔和14%的黑人，31%的居民生活在贫困线以下，癌症是潜在寿命损失的主要原因。因此，我们面临的挑战是在我们的社区发展预防、控制和治疗癌症的科学和服务。我们的具体目标是：1)吸引和教育潜在的研究参与者，特别是少数族裔和弱势群体，使他们了解如何参与最先进的癌症临床研究；2)让参与者参与他们的临床研究并告知他们研究结果；3)向我们的研究人员，包括当地医学界的研究人员提供NCI赞助的临床合作小组试验和药物研究的菜单，用于筛查、预防、癌症控制和治疗；以及4)与新重组的NCI临床合作小组建立密切关系，以提高临床研究的效益。在过去的三年里，RRMO和临床试验管理办公室(CRMO)联合招募了3342名受试者参加干预性研究，包括治疗试验、预防和癌症控制研究以及生存计划。我们已经招募了超过2,502名少数民族受试者参加临床试验，其中大多数是由NCI赞助的。尽管RRMO很有效，但它并不招募所有的研究人员。有了MBCCOP，我们将能够通过以下方式将外展扩展到更广泛的参与者：1)支持更广泛的肿瘤学专科试验的外展招聘，例如儿科、外科专科和更多的内科肿瘤学试验等；2)它将使我们能够开展更多的癌症控制和预防研究，因为将通过MBCCOP获得额外的资源。这将使我们能够全面了解疾病、年龄和治疗范围，拓宽器官/部位专科的范围，并让更多的少数族裔患者参加更广泛的癌症研究试验。

DESCRIPTION (provided by applicant): The Herbert Irving Comprehensive Cancer Center of the Columbia University Medical Center is located in northern Manhattan, New York. In our neighborhood, which is 71% Hispanic and 14% Black, 31% of residents are living below the poverty level, and cancer is the leading cause of years of potential life lost. Our challenge is therefore to develop the science and the services to prevent, control, and treat cancer in our community. Our specific objectives are: 1) to attract and educate potential study participants, especially minorities and the underserved, about participation in state-of-the-art cancer clinical research; 2) to keep participants engaged in their clinical studies and inform them of research results; 3) to provide a menu of NCI-sponsored Clinical Cooperative Group trials and pharmaceutical studies to our investigators, including those in the local medical community, for screening, prevention, cancer control, and treatments; and 4) to establish close relationships with the newly restructured NCI Clinical Cooperative Groups to enhance the benefits of clinical research. In the past three years, the RRMO and the Clinical Trials Management Office (CRMO) have combined to recruit more than 3,342 subjects to interventional studies, including, therapeutic trials, prevention and cancer control studies and survivorship initiatives. We have enrolled more than more than 2,502 minority subjects in clinical trials, most of them NCI-sponsored. Despite the effectiveness of the RRMO, it does not recruit for all studies. With an MBCCOP we will be able to expand the outreach to a broader range of participants by 1) supporting outreach recruitment to a wider range of oncology subspecialty trials, e.g. pediatrics, surgical specialties, and more medical oncology trials, etc. and 2) it will allow us to open more cancer control and prevention studies as there will be additional resources available through the MBCCOP. This will allow us to be comprehensive across the disease, age and treatment spectrum and broaden the range of organ/site specialties and to enroll still more minority patients in a wider range of cancer research trials.